The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line (1L) FOLFIRINOX (FFX): Bridging the gap between the NAPOLI 3 trial and real-world practice.
 
Paul Cockrum
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Rose Chang
Research Funding - Ipsen (Inst)
 
Louise Yu
Research Funding - GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Otsuka (Inst); Pfizer (Inst); Takeda (Inst)
 
Chunyi Xu
Research Funding - Abbvie (Inst); Alnylam (Inst); Apellis Pharmaceuticals (Inst); AstraZeneca (Inst); Ferring (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Teva (Inst); Travere Therapeutics (Inst)
 
Mei Sheng Duh
Consulting or Advisory Role - Alexion Pharmaceuticals (I); Jazz Pharmaceuticals (I); Omeros (I)
Research Funding - Abbvie (Inst); Apellis Pharmaceuticals (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Humacyte (Inst); IPSEN (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst)
 
George Kim
Employment - Ipsen (I)
Honoraria - Exelixis; Ipsen
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Ipsen